What is the purpose of the capital alliance between the two companies?

To accelerate the business of 'acquired immunity analysis' and the application to animal drugs by combining Target Healthcare's medical network and Nippon Yakushi's antibody production and AI analysis technology.

What kind of service is the 'acquired immunity analysis business'?

A service that comprehensively analyzes and reports antibody information (immune memory) acquired by an individual from a small blood sample, used for wellness of the affluent and drug discovery support.

What approach will be taken for animal drug development?

Nippon Yakushi will directly utilize the 'zoonotic disease antibody data' researched for human medicine to develop new animal drugs and vaccines.

AI News NQ Analysis

Notice Regarding Capital Alliance and Launch of New Businesses Between Target Healthcare Inc. and Nihon Yakushi Inc.

NQ Score 82/100

N1 Content Completeness 9

AI Summary (NQ-processed)

Target Healthcare and Nihon Yakushi have signed a capital tie-up to accelerate the commercialization of their 'Acquired Immunity Analysis Business' and 'Veterinary Drug Application' using memory B-cell antibody production technology.

AI Analysis

Frequently Asked Questions

Q: What is the purpose of the capital alliance between the two companies?: A: To accelerate the business of 'acquired immunity analysis' and the application to animal drugs by combining Target Healthcare's medical network and Nippon Yakushi's antibody production and AI analysis technology.
Q: What kind of service is the 'acquired immunity analysis business'?: A: A service that comprehensively analyzes and reports antibody information (immune memory) acquired by an individual from a small blood sample, used for wellness of the affluent and drug discovery support.
Q: What approach will be taken for animal drug development?: A: Nippon Yakushi will directly utilize the 'zoonotic disease antibody data' researched for human medicine to develop new animal drugs and vaccines.